Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 15/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 15/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.44 |
| ▸ | PDE2A | O00408 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30573130 | 0.90 | FABP4 (0.66) | FABP4TBXA2RPTGDRPDE2A | |
| SCHEMBL24155321 | 0.90 | FABP4 (0.66) | FABP4TBXA2RPTGDRPDE2A | |
| SCHEMBL24155323 | 0.85 | TBXA2R (0.46) | FABP4TBXA2RPTGDRPDE2A | |
| SCHEMBL26247007 | 0.85 | TBXA2R (0.55) | FABP4TBXA2RPTGDRF10PDE2A | |
| SCHEMBL30317268 | 0.85 | FABP4 (0.63) | FABP4TBXA2RPTGDR | |
| SCHEMBL25936205 | 0.85 | TBXA2R (0.46) | FABP4TBXA2RPTGDRPDE2A | |
| SCHEMBL28983470 | 0.85 | FABP4 (0.57) | FABP4TBXA2RPTGDRPDE2A | |
| SCHEMBL30317536 | 0.85 | FABP4 (0.57) | FABP4TBXA2RPTGDRPDE2A | |
| SCHEMBL28983479 | 0.82 | FABP4 (0.62) | FABP4TBXA2RPTGDR | |
| SCHEMBL28983412 | 0.82 | FABP4 (0.43) | FABP4TBXA2RPTGDRPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | FABP1, FABP4, FABP5 | FABP4 2/4885TBXA2R 1741/4885PTGDR 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.